77210-49-2

Basic information

• Product Name: (R)-(FLUOROMETHYL)-BENZENEETHANAMINE
• Synonyms: (R)-(FLUOROMETHYL)-BENZENEETHANAMINE
• CAS NO: 77210-49-2
• Molecular Formula: C9H12FN
• Molecular Weight: 153.2
• Mol File: 77210-49-2.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (R)-(FLUOROMETHYL)-BENZENEETHANAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-(FLUOROMETHYL)-BENZENEETHANAMINE(77210-49-2)
• EPA Substance Registry System: (R)-(FLUOROMETHYL)-BENZENEETHANAMINE(77210-49-2)

Safety Data

• Hazardous Substances Data: 77210-49-2(Hazardous Substances Data)

Upstream product

• 503-20-8 fluoroacetonitrile 
• 6921-34-2 benzylmagnesium chloride 
• 336783-89-2 (2-azido-3-fluoro-propyl)benzene 
• 73058-30-7 (2S)-2-benzylazacyclopropane 
• 77184-95-3 R-(+)-2-benzylaziridine 
• 870839-74-0 (R)-2-(1-fluoromethyl-2-phenylethyl)isoindol-1,3-dione 
• 152903-44-1 (+)-(R)-2-(1-benzyl-2-hydroxyethyl)-1H-isoindole-1,3(2H)-dione 

Relevant articles and documents

Cinnamide compound

The present invention relates to a compound represented by Formula (I): (wherein Ar1 represents an imidazolyl group which may be substituted with 1 to 3 substituents; Ar2 represents a pyridinyl group, a pyrimidinyl group, or a phenyl group which may be substituted with 1 to 3 substituents; X1 represents (1) —C≡C— or (2) a double bond etc. which may be substituted; R1 and R2 represent, for example, a C1-6 alkyl group or C3-8 cycloalkyl group which may be substituted) or a pharmacologically acceptable salt thereof and to the use thereof as pharmaceutical agents. The object of the present invention is to find a therapeutic or preventive agent for diseases caused by Aβ. According to the present invention, a therapeutic or preventive agents for diseases caused by Aβ can be provided.

Synthesis and biochemical evaluation of 3-fluoromethyl-1,2,3,4- tetrahydroisoquinolines as selective inhibitors of phenylethanolamine N- methyltransferase versus the α2-adrenoceptor

A series of 3-fluoromethyl-1,2,3,4-tetrahydroisoquinolines (3- fluoromethyl-THIQs) was proposed, and their phenylethanolamine N- methyltransferase (PNMT) and α2-adrenoceptor affinities were predicted through the use of comparative molecular field analysis (CoMFA) models. These compounds were synthesized and evaluated for affinity at PNMT and the α2- adrenoceptor. It was discovered that these compounds are some of the most selective inhibitors of PNMT versus the α2-adrenoceptor known. To determine the ability of these compounds to penetrate the blood-brain barrier (BBB), a series of THIQs possessing a variety of calculated partition coefficients (Clog P) were assayed using an in vitro BBB model. This study found a good correlation between lipophilicity (Clog P) and BBB permeability, which indicated that THIQs possessing Clog P values of at least 0.13-0.57 should have some penetration into the brain. Two compounds [3-fluoromethyl-7-N-(4- chlorophenyl)aminosulfonyl-THIQ (18) and 3-fluoromethyl-7-cyano-THIQ (20)] possess calculated partition coefficients greater than 0.57 and display selectivities (α2-adrenoceptor K/PNMT K1) greater than 200 and thus represent promising leads in the development of highly selective inhibitors of PNMT with the ability to penetrate the BBB.